Meet Ishwaria Subbiah, M.D.
Ishwaria M. Subbiah, M.D., M.S.
Department of Palliative, Rehabilitation and Integrative Medicine, Division of Cancer Medicine
About Dr. Subbiah
Dr. Ishwaria Subbiah is a medical oncologist and a palliative care and integrative medicine physician and serves as the Director of Faculty and Academic Wellness in the Office of the Chief Academic Officer (CAO) at the University of Texas MD Anderson Cancer Center. As the Director of Faculty and Academic Wellness, Dr. Subbiah provides oversight and support of MD Anderson's initiatives aimed at optimizing the workplace experience of the nearly 1,800 clinical and research faculty in addition to partnering with the Workforce Wellness team to serve our 22,000 employees. To that end, her office prioritizes Building Community & Engagement and Addressing Operational Inefficiencies in cancer care delivery as two key components of professional wellbeing.
Dr. Subbiah is uniquely qualified, having completed three clinical fellowships at MD Anderson in developmental therapeutics, medical oncology, and palliative medicine, all collectively forming her robust foundation in oncology practice and data-driven holistic care. She has an extensive expertise in measures development, creating, and validating novel instruments for behavioral health and holds several peer-reviewed grants including from the American Cancer Society (ACS), the Andrew Sabin Family Foundation, and the Southwest Oncology Group (SWOG)/Hope Foundation. She is the principal investigator on the global study for the comprehensive characterization of clinician experience and wellness during the pandemic and, in the process, developed and validated a novel measure of preparedness and self-efficacy.
In her 10 years at MD Anderson, Dr. Subbiah has led teams that developed and implemented multiple institution-level programs to optimize patient outcomes and the clinical workplace experience. Dr. Subbiah chairs the Patient Survey Informatics Committee overseeing the institution-wide implementation of patient-reported outcomes (PROs) into clinical practice. She also serves on the national Technical Expert Panel developing oncology PRO measures for the Centers for Medicare & Medicaid Services (CMS) and on the Older Adult Oncology guidelines committee of the National Comprehensive Cancer Network (NCCN). Dr. Subbiah cultivates a clinical, research, and administrative presence that consistently empowers multi-stakeholder teams to identify needs of others and to design and implement solutions marked by innovation, impact, scalability, and compassion.
Her ardent institutional, national, and international advocacy reflect her commitment to advance the model of cancer care driven by a dedicated and engaged workforce where cutting edge anti-cancer therapies are seamlessly and synergistically integrated with holistic person-centered care to ultimately deliver a cancer treatment experience in line with the values of each patient and family.
Present Title & Affiliation
Primary Appointment
Director, Faculty and Academic Wellness, Office of the Chief Academic Officer (CAO), The University of Texas MD Anderson Cancer Center, Houston, TX
Assistant Professor, The University of Texas MD Anderson Cancer Center, Houston, TX
Research Interests
Areas of ongoing research include:
comprehensive characterization of clinician experience and wellness during the pandemic development and validation of a novel measure of clinician preparedness and self-efficacy during public health events integration of patient reported outcomes (PROs) and remote symptom monitoring into early phase clinical trials older adult participation in early phase clinical trials implementation of PROs and remote symptom monitoring into routine oncologic careClinical Interests
Dr. Subbiah maintains an active clinical practice in the Division of Cancer Medicine focused on integrative medicine approaches to comprehensive symptom management of persons with cancers with a particular emphasis on improving clinical trial participation especially older adults aged 65 years and above, who remain underrepresented in cancer clinical trials overall.
Education & Training
Degree-Granting Education
| 2019 | Rice University Doerr Institute for New Leaders, MD Anderson Leadership Institute, Houston, TX, USA, Certificate, CoachRice: A Leadership Coaching Program |
| 2018 | Jessie H. Jones Graduate School of Business, Rice University, Houston, TX, USA, Certificate, Health Care Management |
| 2008 | St. George’s University, St. George, GRN, MD, Doctor of Medicine |
| 2005 | Johns Hopkins University, Baltimore, MD, USA, MS, Biotechnology |
| 2004 | Johns Hopkins University, Baltimore, MD, USA, BS, Molecular and Cellular Biology |
Postgraduate Training
| 2018-2019 | Butler-Williams Scholar, National Institutes of Health (NIH), National Institute on Aging (NIA), Bethesda, MD |
| 2015-2016 | Clinical Fellowship, Hospice and Palliative Medicine, University of Texas MD Anderson Cancer Center, Houston, TX |
| 2012-2015 | Clinical Fellowship, Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX |
| 2011-2012 | Clinical Fellowship, Investigational Cancer Therapeutics (A Phase I Program), University of Texas MD Anderson Cancer Center, Houston, TX |
| 2009-2011 | Clinical Residency, Internal Medicine, University of Texas Health Science Center at Houston, Houston, TX |
| 2008-2009 | Clinical Internship, Internal Medicine, Albany Medical Center, Albany, NY |
Board Certifications
| 2016 | American Board of Internal Medicine, Hospice and Palliative Medicine |
| 2015 | American Board of Internal Medicine |
Experience & Service
Administrative Appointments/Responsibilities
Committee Chair, Employee Engagement Council, The University of Texas MD Anderson Cancer Center, Houston, TX, 2021 - Present
Committee Chair, Patient Survey Informatics Committee, The University of Texas MD Anderson Cancer Center, Houston, TX, 2018 - Present
Other Appointments/Responsibilities
Member, Older Adult Oncology Clinical Practice Guidelines Committee, National Comprehensive Cancer Network (NCCN), Fort Washington, PA, 2018 - Present
Institutional Committee Activities
Member, Patient Care Informatics Committee (PCI), 2021 - Present
Member, MD Anderson Research Policy Advisory Council, 2021 - Present
Member, MD Anderson Diversity Council, 2020 - Present
Clinical Lead, Patient-Reported Outcomes, MD Anderson Data-Driven Determinants for COVID-19 Oncology Discovery Effort (D3CODE), 2020 - Present
Member, Faculty Vitality Task Force, Office of the Chief Academic Officer, 2019 - 2020
Member, Primary Palliative Care Acute Care Team (ACT), Department of Emergency Medicine, 2018 - Present
Member, Graduate Medical Education (GME) Diversity & Disparities Committee, 2017 - 2019
Member, Graduate Medical Education (GME) Wellness and Career Sustainability Committee, 2017 - 2019
Selection Committee Member, MD Anderson Faculty and Alumni Development Endowed Fellowship Award Committee, 2017 - 2020
Member, ACGME Program Evaluation Committee, MD Anderson Hospice and Palliative Medicine Fellowship Program, 2016 - 2022
Member, Candidate Selection Committee, MD Anderson Hospice and Palliative Medicine Fellowship Program, 2016 - 2022
Honors & Awards
| 2020 | 2020 Breakthrough Woman Award, Greater Houston Women's Chamber of Commerce |
| 2019 | Andrew Sabin Family Foundation Fellowship |
| 2019 | Worldwide Innovative Network (WIN) in Personalized Cancer Medicine - 2019 Symposium Best Poster Award, WIN Consortium |
| 2017 | Young Investigator Award Finalist, The International Society of Geriatric Oncology (SIOG) |
| 2016 | Conquer Cancer Foundation Merit Award, American Society of Clinical Oncology |
| 2013 | Conquer Cancer Foundation Merit Award, American Society of Clinical Oncology |
| 2013 | AACR-GlaxoSmithKline Outstanding Clinical Scholar Award, American Association for Cancer Research |
| 2013 | Marion D. Edwards Fellowship in Hepatic Oncology, MD Anderson Alumni and Faculty Association |
| 2013 | Extramural Award for Patient-oriented Research Loan Repayment Program, National Institutes of Health (NIH) |
| 2012 | Trainee Excellence Award, MD Anderson Alumni and Faculty Association |
| 2012 | AACR-Warner Fund Scholar-in-Training Award, American Association for Cancer Research |
| 2012 | Finalist, Bristol-Myers Squibb Award, Postgraduate Clinical/Translational Research, MD Anderson Alumni and Faculty Association |
| 2012 | ASCO/AACR Methods in Clinical Trials Workshop, American Society of Clinical Oncology/American Association for Cancer Research |
| 2010 | American College of Gastroenterology Presidential Poster Award, American College of Gastroenterology |
| 2010 | Merit/Travel Award winner for the American Society of Hematology (ASH)/Hemophilia and Thrombosis Research Society (HTRS) Coagulation Disorders Workshop, American Society of Hematology (ASH)/Hemophilia and Thrombosis Research Society (HTRS) |
| 2003 | Beta Beta Beta Honor Society, Johns Hopkins University |
| 2003 | Office of Student Involvement Leadership Award, Johns Hopkins University |
| 2003 | The Chester Wickwire Diversity Award, Johns Hopkins University |
| 2003 | Dean’s List, Johns Hopkins University |
| 2002 | Dean’s List, Johns Hopkins University |
Professional Memberships
Selected Publications
Peer-Reviewed Articles
- Liposits G, Akagunduz B, Rodgers L, Roy M, Velasco RN, Subbiah IM, Marinho J. Highlighting selected research conducted in older patients presented at the 23rd European Society for Medical Oncology (ESMO) World Congress on Gastrointestinal Cancer (2021): Young International Society of Geriatric Oncology Report. J Geriatr Oncol 13(1):4-6, 2022. e-Pub 2021. PMID: 34688559.
- Wang XS, Srour SA, Whisenant M, Subbiah IM, Chen TH, Ponce D, Gonzalez AG, Kamal M, Mendoza T, Cleland CS, Kebriaei P, Neelapu SS, Rezvani K, Ahmed S, Shpall E. Patient-Reported Symptom and Functioning Status during the First 12 Months after Chimeric Antigen Receptor T Cell Therapy for Hematologic Malignancies. Transplant Cell Ther 27(11):930.e1-930.e10, 2021. e-Pub 2021. PMID: 34265479.
- Christopherson KM, Das P, Berlind C, Lindsay WD, Ahern C, Smith BD, Subbiah IM, Koay EJ, Koong AC, Holliday EB, Ludmir EB, Minsky BD, Taniguchi CM, Smith GL. A Machine Learning Model Approach to Risk-Stratify Gastrointestinal (GI) Cancer Patients for Hospitalization and Mortality Outcomes. Int J Radiat Oncol Biol Phys 111(1):135-142, 2021. e-Pub 2021. PMID: 33933480.
- Dotan E, Walter LC, Browner IS, Clifton K, Cohen HJ, Extermann M, Gross C, Gupta S, Hollis G, Hubbard J, Jagsi R, Keating NL, Kessler E, Koll T, Korc-Grodzicki B, McKoy JM, Misra S, Moon D, O'Connor T, Owusu C, Rosko A, Russell M, Sedrak M, Siddiqui F, Stella A, Stirewalt DL, Subbiah IM, Tew WP, Williams GR, Hollinger L, George GV, Sundar H. NCCN Guidelines® Insights: Older Adult Oncology, Version 1.2021. J Natl Compr Canc Netw 19(9):1006-1019, 2021. e-Pub 2021. PMID: 34551388.
- Premnath N, Sumarsono A, Sedhom R, Johnson DH, Subbiah IM, Dy SM, Gupta A. Use of Peripheral μ-Opioid Receptor Antagonists for Treating Opioid-Induced Constipation among US Medicare Beneficiaries from 2014 to 2018. J Palliat Med 24(8):1236-1239, 2021. e-Pub 2021. PMID: 33872062.
- Subbiah IM, Charone MM, Roszik J, Haider A, Vidal M, Wong A, Bruera E. Association of Edmonton Symptom Assessment System Global Distress Score with Overall Survival in Patients with Advanced Cancer. JAMA Network Open, 2021.
- Ganeshan D, Kambadakone A, Nikolaidis P, Subbiah V, Subbiah IM, Devine C. Current update on gallbladder carcinoma. Abdom Radiol (NY) 46(6):2474-2489, 2021. e-Pub 2021. PMID: 33386907.
- Mayo SJ, Lustberg M, M Dhillon H, Nakamura ZM, Allen DH, Von Ah D, C Janelsins M, Chan A, Olson K, Tan CJ, Toh YL, Oh J, Grech L, Cheung YT, Subbiah IM, Petranovic D, D'Olimpio J, Gobbo M, Koeppen S, Loprinzi CL, Pang L, Shinde S, Ntukidem O, Peters KB. Cancer-related cognitive impairment in patients with non-central nervous system malignancies: an overview for oncology providers from the MASCC Neurological Complications Study Group. Support Care Cancer 29(6):2821-2840, 2021. e-Pub 2020. PMID: 33231809.
- Subbiah IM*, Dhawan N*, Yeh JC, Thompson B, Hildner Z, Jawed A, Prommer E, Sinclair C. (*Co-equal first authors). Healthcare Disparities and the COVID-19 Pandemic: Analysis of Primary Language and Translations of Visitor Policies at NCI-designated Comprehensive Cancer Centers. J Pain Symptom Manage 61(5):e13-e16, 2021. e-Pub 2021. PMID: 33561493.
- Desai A, Gainor JF, Hegde A, Schram AM, Curigliano G, Pal S, Liu SV, Halmos B, Groisberg R, Grande E, Dragovich T, Matrana M, Agarwal N, Chawla S, Kato S, Morgan G, Kasi PM, Solomon B, Loong HH, Park H, Choueiri TK, Subbiah IM, Pemmaraju N, Subbiah V, COVID19 and Cancer Clinical Trials Working Group. COVID-19 vaccine guidance for patients with cancer participating in oncology clinical trials. Nat Rev Clin Oncol 18(5):313-319, 2021. e-Pub 2021. PMID: 33723371.
- Dhawan N, Prommer E, Sinclair CT, Subbiah IM. Development of a Patient-Centered Framework for Oncology Clinicians to Address Uncertainty in Cancer Care During the COVID-19 Pandemic. Curr Treat Options Oncol 21(12):99, 2020. e-Pub 2020. PMID: 33119833.
- Abi Jaoude J, Kouzy R, Mainwaring W, Lin TA, Miller AB, Jethanandani A, Espinoza AF, Pasalic D, Verma V, VanderWalde NA, Smith BD, Smith GL, Fuller CD, Das P, Minsky BD, Rödel C, Fokas E, Jagsi R, Thomas CR, Subbiah IM, Taniguchi CM, Ludmir EB. Performance Status Restriction in Phase III Cancer Clinical Trials. J Natl Compr Canc Netw 18(10):1322-1326, 2020. e-Pub 2020. PMID: 33022640.
- Pasalic D, McGinnis GJ, Fuller CD, Grossberg AJ, Verma V, Mainwaring W, Miller AB, Lin TA, Jethanandani A, Espinoza AF, Diefenhardt M, Das P, Subbiah V, Subbiah IM, Jagsi R, Garden AS, Fokas E, Rödel C, Thomas CR, Minsky BD, Ludmir EB. Progression-free survival is a suboptimal predictor for overall survival among metastatic solid tumour clinical trials. Eur J Cancer 136:176-185, 2020. e-Pub 2020. PMID: 32702645.
- Lin TA, Fuller CD, Verma V, Mainwaring W, Espinoza AF, Miller AB, Jethanandani A, Pasalic D, Das P, Minsky BD, Thomas CR, Fogelman DR, Subbiah V, Subbiah IM, Ludmir EB. Trial Sponsorship and Time to Reporting for Phase 3 Randomized Cancer Clinical Trials. Cancers (Basel) 12(9), 2020. e-Pub 2020. PMID: 32947844.
- Adashek JJ, Subbiah IM. Caring for the caregiver: a systematic review characterising the experience of caregivers of older adults with advanced cancers. ESMO Open 5(5):e000862, 2020. PMID: 32963088.
- Battisti NML, Lok WCW, Subbiah I, Okonji D, Desideri I, Soto-Perez-De-Celis E. Perspectives on geriatric oncology research presented at the 2019 San Antonio Breast Cancer Symposium. J Geriatr Oncol 11(4):740-744, 2020. e-Pub 2020. PMID: 32044301.
- Ludmir EB, Subbiah IM, Mainwaring W, Miller AB, Lin TA, Jethanandani A, Espinoza AF, Mandel JJ, Fang P, Smith BD, Smith GL, Pinnix CC, Sedrak MS, Kimmick GG, Stinchcombe TE, Jagsi R, Thomas CR, Fuller CD, VanderWalde NA. Decreasing incidence of upper age restriction enrollment criteria among cancer clinical trials. J Geriatr Oncol 11(3):451-454, 2020. e-Pub 2019. PMID: 31711757.
- Magnuson A, Li D, Hsu T, Loh KP, MacKenzie A, Presley CJ, Krok-Schoen JL, Subbiah IM, Williams GR, Wong M, Soto-Perez-de-Celis E, Sedrak MS, Junior Cancer and Aging Research Group. Mentoring pearls of wisdom: Lessons learned by mentees of Arti Hurria, MD. J Geriatr Oncol 11(2):335-337, 2020. e-Pub 2019. PMID: 31160209.
- Subbiah IM, Lundebjerg N, Appleby J, Wallach G, Beilenson J, Dale W. Development of a strategic plan for the dissemination and communication of aging research through the Cancer and Aging Research Group (CARG) infrastructure grant. J Geriatr Oncol 11(2):359-360, 2020. e-Pub 2019. PMID: 31353236.
- Adashek JJ, Subbiah IM, Matos I, Garralda E, Menta AK, Ganeshan DM, Subbiah V. Hyperprogression and Immunotherapy: Fact, Fiction, or Alternative Fact?. Trends Cancer 6(3):181-191, 2020. e-Pub 2020. PMID: 32101722.
- Sheikh AR, Hsu T, Subbiah IM, Arora SP. Perspectives on Geriatric Oncology Research presented at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting. J Geriatr Oncol 10(6):998-1002, 2019. e-Pub 2019. PMID: 31326394.
- Adashek JJ, Subbiah IM, Subbiah V. Artificial Intelligence Systems Assisting Oncologists? Resist and Desist or Enlist and Coexist. Oncologist 24(10):1291-1293, 2019. e-Pub 2019. PMID: 31337656.
- Chan A, Hertz DL, Morales M, Adams EJ, Gordon S, Tan CJ, Staff NP, Kamath J, Oh J, Shinde S, Pon D, Dixit N, D'Olimpio J, Dumitrescu C, Gobbo M, Kober K, Mayo S, Pang L, Subbiah I, Beutler AS, Peters KB, Loprinzi C, Lustberg MB. Biological predictors of chemotherapy-induced peripheral neuropathy (CIPN): MASCC neurological complications working group overview. Support Care Cancer 27(10):3729-3737, 2019. e-Pub 2019. PMID: 31363906.
- Subbiah IM, Hamilton E, Knoll M, Shanahan K, Meisel J. A Big World Made Small: Using Social Media to Optimize Patient Care. Am Soc Clin Oncol Educ Book 39(39):e212-e218, 2019. e-Pub 2019. PMID: 31099651.
- Menta AK, Subbiah IM, Subbiah V. Bringing wearable devices into oncology practice: fitting smart technology in the clinic. Discov Med 26(145):261-270, 2018. PMID: 30695675.
- Subbiah IM, Tang C, Rao A, Falchook GS, Subbiah V, Tsimberidou AM, Karp D, Kurzrock R, Hong DS. Older adults in phase I clinical trials: a comparative analysis of participation and clinical benefit rate among older adults versus middle age and AYA patients on phase I clinical trials with VEGF/VEGFR inhibitors. Oncotarget 9(48):28842-28848, 2018. e-Pub 2018. PMID: 29989021.
- Sen S, Hess K, Hong DS, Naing A, Piha-Paul S, Janku F, Fu S, Subbiah IM, Liu H, Khanji R, Huang L, Moorthy S, Karp DD, Tsimberidou A, Meric-Bernstam F, Subbiah V. Development of a prognostic scoring system for patients with advanced cancer enrolled in immune checkpoint inhibitor phase 1 clinical trials. Br J Cancer 118(6):763-769, 2018. e-Pub 2018. PMID: 29462132.
- Subbiah IM, Tsimberidou A, Subbiah V, Janku F, Roy-Chowdhuri S, Hong DS. Next generation sequencing of carcinoma of unknown primary reveals novel combinatorial strategies in a heterogeneous mutational landscape. Oncoscience 4(5-6):47-56, 2017. e-Pub 2017. PMID: 28781987.
- Subbiah IM, Wheler JJ, Hess KR, Hong DS, Naing A, Fu S, Kurzrock R, Tsimberidou AM. Outcomes of patients 65 years old with advanced cancer treated on phase I trials at MD Anderson Cancer Center. Int J Cancer 140(1):208-215, 2017. e-Pub 2016. PMID: 27599876.
- Heilmann AM, Subbiah V, Wang K, Sun JX, Elvin JA, Chmielecki J, Sherman SI, Murthy R, Busaidy NL, Subbiah I, Yelensky R, Nangia C, Vergilio JA, Khan SA, Erlich RL, Lipson D, Ross JS, Miller VA, Shah MH, Ali SM, Stephens PJ. Comprehensive Genomic Profiling of Clinically Advanced Medullary Thyroid Carcinoma. Oncology 90(6):339-46, 2016. e-Pub 2016. PMID: 27207748.
- Subbiah IM, Falchook GS, Kaseb AO, Hess KR, Tsimberidou AM, Fu S, Subbiah V, Hong DS, Naing A, Piha-Paul SA, Akmal O, Janku F, Kurzrock R. Exploring response signals and targets in aggressive unresectable hepatocellular carcinoma: an analysis of targeted therapy phase 1 trials. Oncotarget 6(29):28453-62, 2015. PMID: 26164085.
- Subbiah V, Berry J, Roxas M, Guha-Thakurta N, Subbiah IM, Ali SM, McMahon C, Miller V, Cascone T, Pai S, Tang Z, Heymach JV. Systemic and CNS activity of the RET inhibitor vandetanib combined with the mTOR inhibitor everolimus in KIF5B-RET re-arranged non-small cell lung cancer with brain metastases. Lung Cancer 89(1):76-9, 2015. e-Pub 2015. PMID: 25982012.
- Subbiah IM, Lei X, Weinberg JS, Sulman EP, Chavez-MacGregor M, Tripathy D, Gupta R, Varma A, Chouhan J, Guevarra RP, Valero V, Gilbert MR, Gonzalez-Angulo AM. Validation and Development of a Modified Breast Graded Prognostic Assessment As a Tool for Survival in Patients With Breast Cancer and Brain Metastases. J Clin Oncol 33(20):2239-45, 2015. e-Pub 2015. PMID: 25987700.
- Subbiah V, McMahon C, Patel S, Zinner R, Silva EG, Elvin JA, Subbiah IM, Ohaji C, Ganeshan DM, Anand D, Levenback CF, Berry J, Brennan T, Chmielecki J, Chalmers ZR, Mayfield J, Miller VA, Stephens PJ, Ross JS, Ali SM. STUMP un"stumped": anti-tumor response to anaplastic lymphoma kinase (ALK) inhibitor based targeted therapy in uterine inflammatory myofibroblastic tumor with myxoid features harboring DCTN1-ALK fusion. J Hematol Oncol 8:66, 2015. e-Pub 2015. PMID: 26062823.
- Subbiah IM, Subbiah V. Exceptional responders: in search of the science behind the miracle cancer cures. Future Oncol 11(1):1-4, 2015. PMID: 25572778.
- Subbiah IM, Blackmon SH, Correa AM, Kee B, Vaporciyan AA, Swisher SG, Eng C. Preoperative chemotherapy prior to pulmonary metastasectomy in surgically resected primary colorectal carcinoma. Oncotarget 5(16):6584-93, 2014. PMID: 25051371.
- Subbiah IM, Gonzalez-Angulo AM. Advances and future directions in the targeting of HER2-positive breast cancer: implications for the future. Curr Treat Options Oncol 15(1):41-54, 2014. PMID: 24323591.
- Subbiah V, Subbiah IM. Killing two birds with one stone: BRAF V600E inhibitor therapy for hairy cell leukemia and Langerhans/dendritic cell sarcoma. Ann Hematol 92(8):1149, 2013. e-Pub 2013. PMID: 23322213.
- Tsimberidou AM, Leick MB, Lim J, Fu S, Wheler J, Piha-Paul SA, Hong D, Falchook GS, Naing A, Subbiah IM, Fortier A, Avritscher R, Kurzrock R. Dose-finding study of hepatic arterial infusion of oxaliplatin-based treatment in patients with advanced solid tumors metastatic to the liver. Cancer Chemother Pharmacol 71(2):389-97, 2013. e-Pub 2012. PMID: 23143207.
- Subbiah IM, Subbiah V, Tsimberidou AM, Naing A, Kaseb AO, Javle M, Fu S, Hong DS, Piha-Paul S, Wheler JJ, Hess KR, Janku F, Falchook GS, Wolff RA, Kurzrock R. Targeted therapy of advanced gallbladder cancer and cholangiocarcinoma with aggressive biology: eliciting early response signals from phase 1 trials. Oncotarget 4(1):156-65, 2013. PMID: 23391555.
- Kaseb AO, Shama M, Sahin IH, Nooka A, Hassabo HM, Vauthey JN, Aloia T, Abbruzzese JL, Subbiah IM, Janku F, Curley S, Hassan MM. Prognostic indicators and treatment outcome in 94 cases of fibrolamellar hepatocellular carcinoma. Oncology 85(4):197-203, 2013. e-Pub 2013. PMID: 24051705.
- Tsimberidou AM, Fu S, Subbiah IM, Naing A, Hong DS, Wen S, Fortier AH, Lim J, Kurzrock R. Intraperitoneal and intravenous chemotherapy in peritoneal carcinomatosis. Hepatogastroenterology 59(116):960-4, 2012. PMID: 22580643.
- Subbiah IM, Lenihan DJ, Tsimberidou AM. Cardiovascular toxicity profiles of vascular-disrupting agents. Oncologist 16(8):1120-30, 2011. e-Pub 2011. PMID: 21742963.
- Subbiah IM*, Yeh JC*, Dhawan N, Thompson BW, Hildner Z, Jawed A, Prommer E, Sinclair CT. (*Coequal first authors). Visitation Policies at NCI-Designated Comprehensive Cancer Centers during the COVID-19 Pandemic. Support Care Cancer. e-Pub 2021. PMID: 33796936.
- Reddy A, Arthur J, Dalal S, Hui D, Subbiah I, Wu J, Anderson AE, Castro D, Joy M, Nweke C, Gogineni M, Maddi R, Rozman de Moraes A, Shelal Z, Bruera E. Rapid Transition to Virtual Care during the COVID-19 Epidemic: Experience of a Supportive Care Clinic at a Tertiary Care Cancer Center. J Palliat Med. e-Pub 2021. PMID: 33535019.
- Kouzy R, Abi Jaoude J, Minsky BD, Das P, Koong AC, Subbiah IM, Ludmir EB, Taniguchi CM. Gastrointestinal malignancies and supportive care trials: a snapshot of the last two decades. BMJ Support Palliat Care. e-Pub 2020. PMID: 32943466.
- Giri S, Chakiba C, Shih YY, Chan WL, Krok-Schoen JL, Presley CJ, Williams GR, Subbiah IM. Integration of geriatric assessment into routine oncologic care and advances in geriatric oncology: A young International Society of Geriatric Oncology Report of the 2020 American Society of Clinical Oncology (ASCO) annual meeting. J Geriatr Oncol. e-Pub 2020. PMID: 32732011.
- Subbiah IM, Markham MJ, Graff SL, Matt-Amaral LB, Close JL, Griffith KA, Jagsi R. Incidence, Nature, and Consequences of Oncologists' Experiences With Sexual Harassment. J Clin Oncol:JCO2102574. e-Pub 2022. PMID: 35089804.
- Gupta A, Nshuti L, Grewal US, Sedhom R, Check DK, Parsons HM, Blaes AH, Virnig BA, Lustberg MB, Subbiah IM, Nipp RD, Dy SM, Dusetzina SB. Financial Burden of Drugs Prescribed for Cancer-Associated Symptoms. JCO Oncol Pract:OP2100466. e-Pub 2021. PMID: 34558297.
- Hui D, Darke AK, Guthrie KA, Subbiah IM, Unger JM, Hershman DL, Krouse RS, Bakitas M, O'Rourke MA. Association between Health-Related Quality of Life and Progression Free Survival in Patients with Advanced Cancer: A Secondary Analysis of SWOG Clinical Trials. JCO Oncol Pract:OP2100407. e-Pub 2021. PMID: 34606328.
- Nipp RD, Subbiah IM, Loscalzo M. Convergence of Geriatrics and Palliative Care to Deliver Personalized Supportive Care for Older Adults With Cancer. J Clin Oncol:JCO2100158. e-Pub 2021. PMID: 34043435.
- Desai A, Subbiah IM, Subbiah V. Advances in cancer research dissemination through the pandemic and beyond. Annals of Oncology. e-Pub 2021. PMID: 33636283.
- Cascone T, Sacks RL, Subbiah IM, Drobnitzky N, Piha-Paul SA, Hong DS, Hess KR, Amini B, Bhatt T, Fu S, Naing A, Janku F, Karp D, Falchook GS, Conley AP, Sherman SI, Meric-Bernstam F, Ryan AJ, Heymach JV, Subbiah V. Safety and activity of vandetanib in combination with everolimus in patients with advanced solid tumors: a phase I study. ESMO Open 6(2):100079. e-Pub 2021. PMID: 33721621.
Manuals, Teaching Aids, Other Teaching Publications
- Ishwaria Subbiah. Focused Assessment and Study Tool (FAST): Psychiatry and Cognition Module, 3rd Edition. American Academy of Hospice and Palliative Medicine, 2017.
Editorials
- Subbiah IM. Integration of End-of-Life Care into Accountable Care Organization's Quality Measures. J Am Geriatr Soc 67(5):877-878, 2019. PMID: 30969433.
- Subbiah IM. Palliative Care in the Time of Hurricane Harvey. Pallimed, 2017.
- Subbiah IM, Tejero I, Alibhai SMH. Multidimensional impact of the geriatric assessment in the cancer care of older adults. Cancer. PMID: 34762733.
Abstracts
- Williams LA, Whisenant M, Mendoza TR, Malveaux D, Griffin D, Ponce D, Cleeland CS, Peek A, Granwehr BP, Hutcheson KA, Shaw KR, Ravi V, Woodman SE, Chung C, Aloia TA, Futreal PA, Jaffray DA, Subbiah IM, on behalf of the MD Anderson Cancer Center D3CODE Team. Development and validation of a novel patient-reported outcomes (PRO) measure for symptom burden in patients with cancer and COVID-19 infection. 2021 ASCO Annual Meeting, 2021. e-Pub 2021.
- Subbiah IM, Williams LA, Peek A, Shete S, Granwehr BP, D'Achiardi D, Turin A, Garcia EA, Finder J, Chemaly R, Beltran K, Shaw KR, Whisenant M, Woodman SE, Ravi V, Tawbi HA, Subbiah V, Chung C, Futreal PA, Jaffray DA, on behalf of the MD Anderson Cancer Center D3CODE Team. Real-world patient-reported and clinical outcomes of BNT162b2 mRNA COVID-19 vaccine in patients with cancer. 2021 ASCO Annual Meeting, 2021. e-Pub 2021.
- Subbiah IM, Markham MJ, Graff SL, Matt-Amaral LB, Close JL, Griffith KA, Jagsi R. Sexual harassment of oncologists. 2021 ASCO Annual Meeting, 2021. e-Pub 2021.
- Subbiah IM, Amaram-Davila JS, Wong A, Shih KK, Anderson AE, Mendoza TR, Williams LA, Reddy AS, Joy MP, Harnden KM, Gaffney ML, Shelal Z, Maddi R, Nelson CLD, De la Cruz VJ, Elder SL, Ray DQ, Subbiah V, Hong DS, Bruera E. Technology-enhanced palliative care for patients with cancer on phase 1 clinical trials. 2021 ASCO Annual Meeting, 2021. e-Pub 2021.
- Loggers ET, Wulff-Burchfield EM, Subbiah IM, Khaki AR, Egan P, Farmakiotis D, Phull H, Nakasone E, Labaki C, Yu PP, Joshi M, Griffiths EA, Wise-Draper TM, Jani C, Thakkar A, Puc M, Hwang C, Mavromatis BH, Shah DP, Warner JL. Code status and outcomes in patients with cancer and COVID-19: A COVID-19 and cancer consortium (CCC19) registry analysis. 2021 ASCO Annual Meeting, 2021. e-Pub 2021.
- Feldman DB, O'Rourke MA, Corn BW, Hudson MF, Agarwal R, Fraser VL, Deininger H, Fowler LA, Subbiah IM. Development and validation of the self-efficacy for medical communication scale. 2021 ASCO Annual Meeting, 2021. e-Pub 2021.
- Subbiah V, Groisberg R, Skefos C, Cleary JM, Subbiah IM, Palma J, Oster M, Young SW, Elvin JA, Sicklick JK, Gaffey S, Ward A, Alexander BM, Lee JJ, De P, Kato S, Kurzrock R. TCF-001 TRACK (Target Rare Cancer Knowledge): A national patient-centric precision oncology trial for rare cancers.v. 2021 ASCO Annual Meeting, 2021. e-Pub 2021.
- Dhawan N, Yeh J, Hildner Z, Thompson B, Jawed A, Prommer E, Sinclair CT, Subbiah IM. Analysis of Visitor Policies and Psychosocial Resources at NCI-designated Comprehensive Cancer Centers during the COVID-19 Pandemic. 2021 MASCC Annual Meeting, 2021.
- Dalal S, Reddy A, Dev R, Subbiah I, Tanco K, Haider A, Bruera E. Pain Experience Among Hospitalized Cancer Patients At A Tertiary Cancer Center. MASCC/ISOO Annual Meeting on Supportive Care in Cancer, 2020.
- Subbiah I, Charone M, Roszik J, Azhar A, De La Cruz M, Haider A, Epner D, delgado Guay M, Reddy A, Vidal M, wong A, Dalal S, Dev R, Arthur J, Reddy S, Bruera E. Prognostic Value Of The Edmonton Symptom Assessment Scale: High ESAS Global Distress Score Associated With Lower Overall Survival In Adv Ca Patients. MASCC/ISOO Annual Meeting on Supportive Care in Cancer, 2020.
- Subbiah IM, Charone M, Subbiah V, Hong DS, Bruera E.. Merging Patient-Centered Care and Early Phase Drug Development: Integration of Patient Reported Outcomes into immunotherapy-based phase I trials. Proceedings of the 2019 Worldwide Innovative Network (WIN) Symposium, 2019.
- Huey RW, Aloia TA, Subbiah IM. Organizing governance for clinical implementation of electronic patient reported outcomes. Proceedings of the 2019 International Consortium for Health Outcomes Measurement (ICHOM) Annual Conference, 2019. e-Pub 2019.
- Subbiah IM. A Comparative Analysis of Participation And Clinical Benefit Among Older Adults Versus Middle Age and AYA Patients on Phase I Clinical Trials with VEGF/VEGFR Inhibitors. MASCC/ISOO Annual Meeting on Supportive Care in Cancer, 2018.
- Subbiah IM, Tang C, Rao A, Subbiah V, Kurzrock R, Hong DS. Call to integrate supportive care and patient reported outcomes in early phase clinical trials: An exploration of adolescent and young adult (AYA) participation on phase I trials of novel anticancer agents. ASCO Palliative and Supportive Care in Oncology Symposium, 2017.
- Subbiah IM, Hess KR, Fujii R, Lui A, Subbiah V, Naing A, Hong DS. Integration of supportive care in immuno-oncology trials: Investigating the incidence and severity of immune-related toxicities among older adults versus mid-age patients on immunotherapy-based phase I clinical trials. ASCO Palliative and Supportive Care in Oncology Symposium, 2017.
- Subbiah IM, Hess KR, Fujii T, Alshawa A, Lui A, Roy S, Khanji R, Subbiah V, Naing A, Hong DS. Immuno-oncology and the elderly: A comparative analysis of participation and toxicities of senior adults aged 65 years and above vs mid age and adolescent/young adult patients on immunotherapy-based phase I clinical trials. J Clin Oncol 35, 2017 (suppl; abstr 10034), 2017. e-Pub 2017.
- Subbiah IM, Tang C, Rao A, Subbiah V, Kurzrock R, Karp D, Hong DS. Clinical benefit rate and participation of patients with advanced cancer on phase I clinical trials: A comparative analysis of senior adults aged 65 years and above versus middle age and AYA patients. J Geriatr Oncol. 7/6S1 (2016) S37–S123, 2016.
- Subbiah IM, Tang C, Rao A, Falchook GS, Subbiah V, Kurzrock R, Karp DD, Hong DS. Participation and response assessment of older adults with advanced cancer treated on phase I trials as compared to middle age and AYA patients: An analysis of 1489 patients. J Clin Oncol 34, 2016 (suppl; abstr 10049), 2016. e-Pub 2016.
- Cascone R, Hess KR, Piha-Paul SA, Hong DS, Subbiah IM, Bhatt R, Fu S, Naing A, Janku F, Karp DD, Meric-Bernstam F, Heymach J, Subbiah V. Safety, toxicity and activity of multi-kinase inhibitor vandetanib in combination with everolimus in advanced solid tumors. J Clin Oncol 34, 2016 (suppl; abstr 9073), 2016. e-Pub 2016.
- Cascone T, Subbiah V, Hess KR, Nelson S, Nilsson MB, Subbiah IM, Ali SM, Carbone DP, Salgia R, Owonikoko TK, Meric-Bernstam F, Doebele RC, Heymach J. Significant systemic and CNS activity of RET inhibitor vandetanib combined with mTOR inhibitor everolimus in patients with advanced NSCLC with RET fusion. J Clin Oncol 34, 2016 (suppl; abstr 9069), 2016. e-Pub 2016.
- Cascone T, Hess KR, Piha-Paul S, Hong DS, Roxas M, Subbiah IM, Fu S, Naing A, Janku F, Karp D, Sherman SI, Meric-Bernstam F, Heymach JV, Subbiah V. A phase I study of everolimus (mTOR inhibitor) in combination with vandetanib (multikinase inhibitor of VEGFR, EGFR, and RET) in advanced solid tumors including molecularly matched aberrations. Mol Cancer Ther Dec 2015, 14 (12 Supplement 2) LB-C17; DOI: 10.1158/1535-7163.TARG-15-LB-C17, 2015.
- Subbiah IM, Varadhachary G, Tsimberidou AM, Wheler JJ, Subbiah V, Janku F, Roy Chowdhuri S, Zinner R, Hong DS. Impaired cell cycle arrest with concurrent epigenetic deregulation identified through next generation sequencing in patients with advanced carcinoma of unknown primary: Implications for personalized medicine. Cancer Res Aug 2015, 75 (15 Supplement) 604; DOI: 10.1158/1538-7445.AM2015-604, 2015.
- Subbiah IM, Janku F, Tsimberidou AM, Naing A, Subbiah V, Wheler JJ, Zinner R, Eng C, Overman MJ, Kopetz S, Hong DS. Concurrent aberrations in the Wnt, MAPK and PI3K pathways identified through next generation sequencing of relapsed refractory colorectal adenocarcinoma (CRC): Implications for future therapeutic trials. Cancer Res Aug 2015, 75 (15 Supplement) 4263; DOI: 10.1158/1538-7445.AM2015-4263, 2015.
- Subbiah IM, Janku F, Tsimberidou AM, Naing A, Subbiah V, Wheler JJ, Zinner R, Eng C, Overman MJ, Kopetz S, Palmer GS, Hong DS. Next-generation sequencing of advanced, relapsed colorectal adenocarcinoma (CRC) to reveal mutations affecting Wnt, MAPK and PI3K pathway signaling: Emergence of novel combinatorial strategies. J Clin Oncol 33, 2015 (suppl 3; abstr 605), 2015.
- Subbiah IM, Varadhachary G, Palmer G, Tsimberidou AM, Wheler JJ, Subbiah V, Janku F, Chowdhuri SR, Zinner R, Meric-Bernstam F, Hong DS. One size does not fit all: Fingerprinting advanced carcinoma of unknown primary through comprehensive profiling identifies aberrant activation of the PI3K and MAPK signaling cascades in concert with impaired cell cycle arrest. Cancer Res Oct 2014, 74 (19 Supplement) 4700; DOI: 10.1158/1538-7445.AM2014-4700, 2014.
- Bupathi M, Falchook GS, Hong DS, Subbiah IM, Piha-Paul SA, Karp DD, Saigal B, Zinner R, Wheler JJ, Tsimberidou AM, Fu S, Sherman SI, Meric-Bernstam F, Subbiah V. A phase 1 trial of vandetanib (multikinase inhibitor of EGFR, VEGFR, and RET) in combination with everolimus (mTOR inhibitor) in patients with advanced malignancies. J Clin Oncol 32:5s, 2014 (suppl; abstr TPS2639), 2014. e-Pub 2014.
- Subbiah IM, Varadhachary GR, Tsimberidou AM, Wheler JJ, Subbiah V, Falchook GS, Janku F, Zinner R, Roy-Chowdhuri S, Meric-Bernstam F, Hong DS. Next-generation sequencing in carcinoma of unknown primary (CUP) and novel combinatorial strategies in a heterogeneous mutational landscape: Implications for personalized medicine. J Clin Oncol 32, 2014 (suppl; abstr e22154), 2014.
- Dasari A, Phan A, Gupta S, Yeung S, Dong M, Culotta K, Hess K, Chen H, Halperin D, Subbiah IM, Meric-Bernstam F, Yao J. A Phase I Study of the Anti-IGF-1R Monoclonal Antibody (MoAb), IMC-A12 (I) and Everolimus (E) in Well Differentiated Neuroendocrine Tumors (WD NET). J Clin Oncol 32, 2014 (suppl 3; abstr 232), 2014.
- Subbiah IM, Dasari A, Escano M, Dagohoy C, Yao JC. Exploratory analysis of early response signals using targeted therapies for the treatment of advanced carcinoid tumor of the kidney. Proceedings of the 2013 North American Neuroendocrine Tumor Society Neuroendocrine Tumor Symposium. October 2013, 2013.
- Subbiah IM, Wheler JJ, Hess KR, Hong DS, Fu S, Wolff RA, Kurzrock R, Tsimberidou AM. Outcomes of patients ≥ 65 yrs with advanced cancer treated on phase I clinical trials. J Clin Oncol 31, 2013 (suppl; abstr 9544), 2013. e-Pub 2013.
- Subbiah IM, Janku F, Naing A, Fu S, Hong DS, Kaseb AO, Herzog C, Kurzrock R, Wolff RA, Subbiah V. Theranostic profiling of adolescents and young adults (AYA) with advanced fibrolamellar hepatocellular carcinoma identifies aberrant activation of the PI3K/AKT/MTOR signaling cascade. Cancer Res Apr 2013, 73 (8 Supplement) 48; DOI: 10.1158/1538-7445.AM2013-48, 2013.
- Subbiah IM, Blackmon SH, Correa AM, Kee BK, Vaporciyan AA, Swisher S, Eng C. Preoperative chemotherapy prior to pulmonary metastatecomy in patients with prior surgically resected primary colorectal carcinoma. J Clin Oncol 31, 2013 (suppl 4; abstr490), 2013. e-Pub 2013.
- Subbiah IM, Janku F, Tsimberidou AM, Naing A, Kaseb AO, Hong DS, Subbiah V, Hess KR, Akmal O, Falchook GS, Kurzrock R. Characteristics and outcomes of patients with advanced hepatocellular carcinoma treated on phase I trials. J Clin Oncol 31, 2013 (suppl 4; abstr281), 2013.
- Subbiah IM, Subbiah V, Naing A, Fu S, Kaseb AO, Falchook GS, Tan D, Herzog CE, Janku F, Kurzrock R. Targeted therapies in early-phase trials for the treatment of advanced fibrolamellar hepatocellular carcinoma. J Clin Oncol 31, 2013 (suppl 4; abstr232), 2013.
- Subbiah IM, Tsimberidou AM, Naing A, Subbiah V, Kaseb AO, Fu S, Hong DS, Piha-Paul SA, Wheler JJ, Janku F, Hess KR, Falchook GS, Kurzrock R. Early-phase trials compared to first- and second-line FDA-approved treatments in patients with advanced gallbladder cancer and cholangiocarcinoma. J Clin Oncol 30, 2012 (suppl; abstr e13020), 2012.
- Subbiah IM, Kurzrock R, Naing A, Piha-Paul S, Falchook GS, Hong DS, Wheler JJ, Fu S, Laday S, Tsimberidou AM. A phase I study of lenalidomide in combination with bevacizumab, sorafenib, temsirolimus, or 5-fluorouracil, leucovorin, oxaliplatin (FOLFOX) in patients with advanced cancers. Cancer Res Apr 2012, 72 (8 Supplement) 1751; DOI: 10.1158/1538-7445.AM2012-1751, 2012.
- Subbiah IM, Tsimberidou AM, Naing A, Subbiah V, Kaseb AO, Falchook GS, Fu S, Hong DS, Piha-Paul SA, Wheler JJ, Janku F, Kurzrock R. Early-phase trials in patients with advanced gallbladder cancer and cholangiocarcinoma: The MD Anderson Clinical Center for Targeted Therapy experience. Cancer Res Apr 2012, 72 (8 Supplement) 2669; DOI: 10.1158/1538-7445.AM2012-2669, 2012.
- Subbiah IM, Subbiah V, Kaseb AO, Janku F, Wheler JJ, Naing A, Fu S, Piha-Paul SA, Hong DS, Falchook GS, Tsimberidou AM, Kurzrock R. Characteristics and outcomes of patients with gallbladder cancer and cholangiocarcinoma referred to a phase I clinic. J Clin Oncol 30, 2012 (suppl 4; abstr 364), 2012.
- Subbiah IM, Cen P, Tanikella R, Bryant KW, Liaw VJ, Fallon MB, Cohen AM. Radioembolization of unresectable primary and secondary hepatic malignancies using yttrium-90: The University of Texas at Houston experience. J Clin Oncol 29: 2011 (suppl 4; abstr 311), 2011.
- Freedland SJ, Luo J, De Marzo AM, Dunn T, Fedor H, Darshan M, Mohan I, Isaacs WB. Gene expression differences between prostate cancers from obese and normal weight men. Cancer Res May 2005, 65 (9 Supplement) 745; DOI:, 2005.
- Sidey-Gibbons C, Sun CC, Xu C, Schneider A, Lu S, Subbiah IM, Wright AA, Meyer LA. Predicting 180-day mortality for women with ovarian cancer using machine learning and patient-reported outcome data. 2021 ASCO Annual Meeting. e-Pub 2021.
- Reddy NK, Roszik J, Norris DC, Groisberg R, Coleman N, Alhalabi O, Ludmir EB, Taniguchi CM, Subbiah IM, Subbiah V. Dosing, drug reduction, drug interruption, and drug discontinuation rates among U.S. FDA approved tyrosine kinase inhibitors. 2021 ASCO Annual Meeting. e-Pub 2021.
- Dev R, Reddy AS, Arthur JA, Haider A, Subbiah IM, Delgado-Guay MO, Carmack CL, Bruera E, Hui D. Adaptive and maladaptive coping strategies among patients with advanced cancer. 2021 ASCO Annual Meeting. e-Pub 2021.
Book Chapters
- Morris V, Subbiah IM, Kopetz S, Eng C. Chapter 21: Colorectal Cancer. In: MD Anderson Manual of Medical Oncology. 3. McGraw Hill Professional: New York, NY USA, 2016.
- Subbiah IM, Eng C, Lou E. The Management of Metastatic Disease. In: Comprehensive Rectal Cancer Care. 1. Pertinax Publishing: United Kingdom, 2015.
- Subbiah IM. Breast Cancer Supportive Care. In: Holland-Frei Cancer Medicine. 10. Wiley Blackwell.
Letters to the Editor
- Subbiah IM, Brown RE, Fallon MB. Activation of the mammalian target of rapamycin signaling pathway in hepatocellular carcinoma. Hepatology 52: 1524, 2010.
Grant & Contract Support
| Title: | Personalizing care guided by patient-reported outcomes: A comprehensive multimodal strategy to ease the suffering of patients and caregivers with advanced blood cancers |
| Funding Source: | Gabrielle’s Angel Foundation for Cancer Research |
| Role: | Principal Investigator |
| Title: | Technology-enhanced Supportive Care for Cancer Patients on Phase 1 Trials |
| Funding Source: | Andrew Sabin Family Foundation |
| Role: | Principal Investigator, 10% |
| Title: | Clinician Scientist Development Grant: Proactive Supportive Care for Patients with Cancer on Clinical Trials |
| Funding Source: | American Cancer Society (ACS) |
| Role: | Principal Investigator |
| Title: | Patient Reported Outcomes-Performance Measures for Oncology Care (PROMOnc) |
| Funding Source: | Pacific Business Group on Health, Centers for Medicare and Medicaid Services (CMS) |
| Role: | Principal Investigator, 0% (no salary support) |
| Title: | Multi-center pilot feasibility study on the integration of a remote learning, virtual curriculum to promote high quality serious-illness conversations among oncology providers |
| Funding Source: | The Hope Foundation for Cancer Research |
| Role: | Principal Investigator, 0% (no salary support) |
| Title: | Texas Alliance for Cancer and COVID Research Discovery: A Data Collaboration Core (TX-ACCORD) |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | Co-Investigator |
| Title: | Characterizing COVID-19 and Cancer to Predict and Personalize Post-Acute Sequelae of SARS-CoV-2 Infection (PASC) Management (C3P3): Recovery Cohort |
| Funding Source: | NIH/NCI |
| Role: | Co-Principal Investigator |
| Title: | Characterizing COVID-19 and Cancer to Predict and Personalize Post-Acute Sequelae of SARS-CoV-2 Infection (PASC) Management (C3P3): Real-World Data |
| Funding Source: | NIH/NCI |
| Role: | Co-Principal Investigator |
| Title: | Greater South Central CTSA/IDeA State Post-Acute Sequelae SARS-CoV-2 Infection Consortium - OTA-21-015B |
| Funding Source: | NIH/NCI |
| Role: | Co-Investigator |
| Title: | Pilot and Exploratory Projects (PEP) in Palliative Care of Cancer Patients and Their Families: Study of Breast Cancer Survivor Symptoms Correlation with Fatigue Measured by Prolonged Wrist Actigraphy |
| Funding Source: | American Cancer Society (ACS) |
| Role: | Co-Investigator |